Biology, asked by Sobhan3299, 1 year ago

Phase i study of the antiangiogenic antibody bevacizumab and the mtor/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity

Answers

Answered by rajputshubhamsingh
0

please see on the branlist

Similar questions